A bedside strategy to overcome the limitations of testing in preclinical models and to determine the role of gene mutations and their targetability directly in patients is presented.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kim Caesar/Nature Publlishing Group
References
Hyman, D.M. et al. Nature 554, 189–194 (2018).
Woodcock, J. & LaVange, L.M. N. Engl. J. Med. 377, 62–70 (2017).
Hyman, D.M. et al. N. Engl. J. Med. 373, 726–736 (2015).
Hainsworth, J.D. et al. J. Clin. Oncol. 36, 536–542 (2018).
AACR Project GENIE Consortium. Cancer Discov. 7, 818–831 (2017).
Acknowledgements
Editorial support was provided by C.M. Micheel.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors are employees of and have stock ownership in Roche/Genentech.
Rights and permissions
About this article
Cite this article
Pao, W., Fodor, I. Catalyzing the field of precision oncology, one basket at a time. Nat Med 24, 387–388 (2018). https://doi.org/10.1038/nm.4530
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4530
This article is cited by
-
Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation
Journal of Cancer Research and Clinical Oncology (2021)
